High-dose paclitaxel with doxorubicin and cyclophosphamide for breast cancer
Author Information
Author(s): Somlo G, Doroshow J H, Synold T, Longmate J, Reardon D, Chow W, Forman S J, Leong L A, Margolin K A, Jr R J Morgan, Raschko J W, Shibata S I, Tetef M L, Yen Y, Kogut N, Schriber J, Alvarnas J
Primary Institution: City of Hope Comprehensive Cancer Center
Hypothesis
The study assesses the feasibility and pharmacokinetics of high-dose infusional paclitaxel in combination with doxorubicin and cyclophosphamide.
Conclusion
The combination of high-dose paclitaxel, doxorubicin, and cyclophosphamide is tolerable and shows promising survival rates in patients with high-risk breast cancer.
Supporting Evidence
- There were no treatment-related deaths.
- Dose-limiting toxicity was reversible, predominantly sensory neuropathy.
- Kaplan–Meier estimates showed 65% event-free survival and 77% overall survival at 30 months.
Takeaway
Doctors tested a strong cancer treatment for breast cancer patients, and it seemed to work well without causing serious harm.
Methodology
Patients received high-dose paclitaxel, doxorubicin, and cyclophosphamide, and their responses and side effects were monitored.
Limitations
The study does not provide long-term outcomes beyond 30 months.
Participant Demographics
Patients included those with high-risk primary breast cancer and stage IV responsive breast cancer.
Statistical Information
Confidence Interval
95% CI; 51–83% for event-free survival, 95% CI; 64–93% for overall survival
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website